Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin Agrees To Symlin Marketing Restrictions In Gaining FDA Approval

Executive Summary

Amylin has agreed to a ban on direct-to-consumer advertising and other marketing restrictions for its diabetes therapy Symlin (pramlintide) as part of FDA's March 16 approval of the drug

You may also be interested in...



Risk Disclosure In Drug Ads Will Be FDA’s Focus After House Defeats DTC Ban

The revised language on direct-to-consumer advertising in the FDA safety bills pending in Congress no longer allows the agency to ban ads, but creates a number of new disclosure requirements for the spots

Risk Disclosure In Drug Ads Will Be FDA’s Focus After House Defeats DTC Ban

The revised language on direct-to-consumer advertising in the FDA safety bills pending in Congress no longer allows the agency to ban ads, but creates a number of new disclosure requirements for the spots

DTC Restrictions Ahead: Risk Management Plans, “Drug Watch” Are Vehicles

FDA will manifest its tougher stance on DTC advertising in requirements for more extensive risk management plans, Hogan & Hartson Partner Robert Brady predicted at a Regulatory Affairs Professionals Society conference in Chicago

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel